Comparing Daily UNICLA-A2 Dairy Products With Conventional Dairy for People at High Risk of Colorectal Cancer After Polyp Removal

What this Trial Is About

Researchers are studying the effects of UNICLA-A2 dairy products on people at high risk of developing colorectal cancer after polypectomy. Colorectal cancer is common and deadly, often developing from precancerous colorectal adenomas. This trial aims to see if switching to UNICLA-A2 products, which contain beta casein A2 protein, higher omega-3 fatty acids, and selenium, can help protect the intestines, reduce inflammation, normalize immune function, and balance gut bacteria. The study compares two groups one consuming UNICLA-A2 milk, yogurt, and fresh cheese daily for three months, and the other consuming conventional dairy products in similar amounts. The dairy intake follows participants usual habits without forcing increased consumption. UNICLA-A2 products have a unique nutrient profile that may reduce harmful gut biofilms and inflammatory markers linked to colorectal cancer risk. Participants will be monitored at the start, after three months, and about one year after their initial colonoscopy. Researchers will measure changes in inflammatory markers like C-reactive protein and tumor necrosis factor alpha, fecal calprotectin, and gut microbiota. They will also track colorectal adenoma recurrence. The study involves regular assessments to understand how dietary changes impact intestinal health and cancer risk over time.

Effects of UNICLA-A2 Dairy Products on Patients at High-risk of Colorectal Cancer Development